MARKET

VYNE

VYNE

Vyne Therapeutics Inc
NASDAQ
1.300
0.000
0.00%
After Hours: 1.300 0 0.00% 19:44 05/09 EDT
OPEN
1.270
PREV CLOSE
1.300
HIGH
1.330
LOW
1.260
VOLUME
81.84K
TURNOVER
--
52 WEEK HIGH
4.300
52 WEEK LOW
1.260
MARKET CAP
19.77M
P/E (TTM)
-1.3899
1D
5D
1M
3M
1Y
5Y
1D
VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating
TipRanks · 1d ago
VYNE Therapeutics GAAP EPS of -$0.20, revenue of $0.2M
Seeking Alpha · 1d ago
*Vyne Therapeutics: Repibresib Gel (VYN201) Phase 2b Vitiligo Top-Line Results Expected in Mid-2025 >VYNE
Dow Jones · 1d ago
*Vyne Therapeutics Has Expected Cash Runway Into 2H 2026 >VYNE
Dow Jones · 1d ago
Weekly Report: what happened at VYNE last week (0428-0502)?
Weekly Report · 4d ago
Weekly Report: what happened at VYNE last week (0421-0425)?
Weekly Report · 04/28 11:18
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)
TipRanks · 04/26 01:50
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 04/25 17:06
More
About VYNE
More
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Recently
Symbol
Price
%Change
    SHW
  • 351.86
  • -0.48%

Webull offers Vyne Therapeutics Inc stock information, including NASDAQ: VYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYNE stock methods without spending real money on the virtual paper trading platform.